| Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD B Kantor, L Tagliafierro, J Gu, ME Zamora, E Ilich, C Grenier, ZY Huang, ... Molecular therapy 26 (11), 2638-2649, 2018 | 166 | 2018 |
| The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson’s disease SNCA mutations V Chen, M Moncalvo, D Tringali, L Tagliafierro, A Shriskanda, E Ilich, ... Human molecular genetics 29 (18), 3107-3121, 2020 | 48 | 2020 |
| Lentiviral vector platform for the efficient delivery of epigenome-editing tools into human induced pluripotent stem cell-derived disease models L Tagliafierro, E Ilich, M Moncalvo, J Gu, A Sriskanda, C Grenier, ... JoVE (Journal of Visualized Experiments), e59241, 2019 | 15 | 2019 |
| IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma SL Swan, N Mehta, E Ilich, SH Shen, DS Wilkinson, AR Anderson, ... Frontiers in Immunology 14, 1085547, 2023 | 14 | 2023 |
| Cytostatic hypothermia and its impact on glioblastoma and survival SF Enam, CY Kilic, J Huang, BJ Kang, R Chen, CS Tribble, E Ilich, ... Science advances 8 (47), eabq4882, 2022 | 9 | 2022 |
| Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia B Arnson, HR Kang, ED Brooks, D Gheorghiu, E Ilich, D Courtney, ... Molecular Therapy Methods & Clinical Development 29, 108-119, 2023 | 4 | 2023 |
| A neural tract-inspired conduit for facile, on-demand biopsy of glioblastoma MI Betancur, A Case, E Ilich, N Mehta, S Meehan, S Pogrebivsky, ST Keir, ... Neuro-Oncology Advances 6 (1), vdae064, 2024 | | 2024 |
| Efficacy of Genome Editing in Infant Mice with Glycogen Storage Disease Type Ia B Arnson, S Li, D Gheorgiu, E Brooks, SO Han, E Ilich, BR Cullen, ... MOLECULAR THERAPY 30 (4), 115-116, 2022 | | 2022 |
| Genome Editing in a Canine Model for Glycogen Storage Disease Type Ia B Arnson, HR Kang, E Brooks, D Gheorghiu, S Li, E Ilich, B Cullen, ... MOLECULAR THERAPY 30 (4), 219-219, 2022 | | 2022 |
| Allele specific targeting of APOE‐E4 expression: The novel CRISRP/CAS9‐based platform for precision therapy for Alzheimer’s disease: Nonhuman: Preclinical studies on APOE and … B Kantor, M Moncalvo, E Ilich, J Rittiner, W Dong, N Asmus, C Falek, ... Alzheimer's & Dementia 16, e036578, 2020 | | 2020 |
| Development of Lentiviral Platform for Allele-Specific Targeted Down-Regulation of APOEe4 Expression: Epigenetic Therapy for Precision Medicine in Alzheimer's Disease B Kantor, J Rittiner, M Moncalvo, E Ilich, W Dong, N Asmus, C Falek, ... MOLECULAR THERAPY 28 (4), 431-432, 2020 | | 2020 |
| Epigenetic Downregulation of ApoE4 for Alzheimer's Disease N Asmus, M Moncalvo, W Dong, E Ilich, C Falek, J Rittiner, D Tringali, ... MOLECULAR THERAPY 28 (4), 430-430, 2020 | | 2020 |
| P2‐050: A NOVEL TARGETED EPIGENOME EDITING SYSTEM FOR FINE DOWNREGULATION OF SNCA LEVELS: TOWARDS PRECISION GENE THERAPY IN PD B Kantor, E Ilich, M Moncalvo, L Tagliafierro, J Gu, A Sriskanda, ... Alzheimer's & Dementia 15, P591-P591, 2019 | | 2019 |
| Integrase-Deficient Lentiviral Vector for Efficient CRISPR/Cas9-Mediated Gene and Epigenome-Editing Applications B Kantor, E Ilich, L Tagliafierro, O Chiba-Falek MOLECULAR THERAPY 27 (4), 101-101, 2019 | | 2019 |
| The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery O Chiba-Falek, L Tagliafierro, E Ilich, A Sriskanda, B Kantor MOLECULAR THERAPY 27 (4), 35-35, 2019 | | 2019 |
